STOCK TITAN

Akumin Stock Price, News & Analysis

AKU NASDAQ

Company Description

Akumin Inc. (NASDAQ: AKU, TSX: AKU) is a prominent U.S.-based provider of comprehensive radiology and oncology services. Serving as a national partner of choice, Akumin collaborates with hospitals, health systems, and physician groups across 48 states, delivering state-of-the-art diagnostic and therapeutic services.

Akumin operates a robust network of 180 owned and/or operated imaging locations, providing a wide range of diagnostic imaging procedures such as MRI, CT, PET/CT, ultrasound, X-ray, mammography, and interventional radiology. Additionally, Akumin offers extensive oncology care, including a full suite of radiation therapy services.

In recent developments, Akumin reported significant financial milestones for the fiscal year ended December 31, 2022. The company achieved a revenue increase of 78% year-over-year, primarily driven by the acquisition of Alliance HealthCare Services. Despite a net loss of $151.6 million for the year, Akumin generated an adjusted EBITDA of $144.1 million, reflecting a substantial growth of 115% over the previous year.

Akumin has also been proactive in addressing industry challenges, such as clinical labor shortages and cost inflation. The company’s transformation initiatives, including site consolidations and operational restructuring, are expected to yield additional run-rate synergies exceeding $25 million in 2023.

Looking forward, Akumin remains focused on enhancing its service offerings and operational efficiency. The company's ongoing integration initiatives and technological advancements, such as the deployment of remote clinical capabilities, aim to deliver significant benefits and support organic growth in the coming years.

Recently, Akumin announced a financial restructuring plan backed by Stonepeak, an alternative investment firm. This plan, which involves a prepackaged chapter 11 process, is designed to strengthen Akumin's balance sheet and secure ample liquidity for future growth. Upon completion, Akumin will transition to a privately-held entity, further streamlining its operations and focusing on its strategic objectives.

Stock Performance

$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$26.3M
Market Cap
91.0M
Shares outstanding

SEC Filings

No SEC filings available for Akumin.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Diluted EPS (TTM)
Operating Cash Flow
Net Profit Margin
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the market cap of Akumin (AKU)?

The market cap of Akumin (AKU) is approximately 26.3M.

What services does Akumin Inc. provide?

Akumin Inc. offers comprehensive radiology and oncology services, including diagnostic imaging such as MRI, CT, PET/CT, ultrasound, X-ray, and mammography, as well as radiation therapy.

How many locations does Akumin operate?

Akumin operates a network of 180 owned and/or operated imaging locations across 48 states in the U.S.

What are Akumin's recent financial achievements?

For the fiscal year ended December 31, 2022, Akumin reported a 78% increase in revenue to $749.6 million and an adjusted EBITDA growth of 115% to $144.1 million.

What is Akumin's approach to overcoming industry challenges?

Akumin addresses industry challenges through transformational initiatives, such as operational restructuring and site consolidations, and by leveraging technological advancements to improve efficiency.

What is the recent financial restructuring plan announced by Akumin?

Akumin has entered a financial restructuring plan with Stonepeak, involving a prepackaged chapter 11 process to strengthen its balance sheet and secure liquidity. The company will transition to a privately-held entity after completion.

How does Akumin support hospitals and health systems?

Akumin provides outsourced radiology and oncology services to approximately 1,000 hospitals and health systems, combining clinical expertise with technological advancements to enhance patient care.

What are Akumin's plans for future growth?

Akumin aims to achieve organic growth through continuous integration initiatives, deployment of remote clinical capabilities, and strategic partnerships with healthcare providers.

What are the key financial metrics for Akumin in recent quarters?

For the second quarter of 2023, Akumin reported revenue of $184.8 million and an adjusted EBITDA of $26.5 million. Despite challenges, the company remains focused on operational efficiency and growth.

Who are Akumin's primary partners?

Akumin collaborates with hospitals, health systems, and physician groups across the United States, providing essential radiology and oncology services.

How can investors obtain more information about Akumin's financial restructuring?

Investors can visit www.AkuminTransaction.com for detailed information about the financial restructuring process and relevant updates.